Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:15115403rdf:typepubmed:Citationlld:pubmed
pubmed-article:15115403lifeskim:mentionsumls-concept:C0005496lld:lifeskim
pubmed-article:15115403lifeskim:mentionsumls-concept:C0596902lld:lifeskim
pubmed-article:15115403lifeskim:mentionsumls-concept:C0220781lld:lifeskim
pubmed-article:15115403lifeskim:mentionsumls-concept:C0023688lld:lifeskim
pubmed-article:15115403lifeskim:mentionsumls-concept:C0220825lld:lifeskim
pubmed-article:15115403lifeskim:mentionsumls-concept:C1883254lld:lifeskim
pubmed-article:15115403lifeskim:mentionsumls-concept:C0205464lld:lifeskim
pubmed-article:15115403lifeskim:mentionsumls-concept:C0243072lld:lifeskim
pubmed-article:15115403pubmed:issue10lld:pubmed
pubmed-article:15115403pubmed:dateCreated2004-4-29lld:pubmed
pubmed-article:15115403pubmed:abstractTextIn our efforts toward developing a nonselective ligand that would block the effects of stimulants such as methamphetamine at dopamine (DA), serotonin (5-HT), and norepinephrine (NE) transporters, we synthesized a series of 3-(3,4-dichlorophenyl)-1-indanamine derivatives. Two of the examined higher affinity compounds had a phenolic hydroxyl group enabling preparation of a medium to long chain carboxylic acid ester that might eventually be useful for a long-acting depot formulation. The in vitro data indicated that (-)-(1R,3S)-trans-3-(3,4-dichlorophenyl)-6-hydroxy-N-methyl-1-indanamine ((-)-(1R,3S)-11) displays high-affinity binding and potent inhibition of uptake at all three biogenic amine transporters. In vivo microdialysis experiments demonstrated that intravenous administration of (-)-(1R,3S)-11 to rats elevated extracellular DA and 5-HT in the nucleus accumbens in a dose-dependent manner. Pretreating rats with 0.5 mg/kg (-)-(1R,3S)-11 elevated extracellular DA and 5-HT by approximately 150% and reduced methamphetamine-induced neurotransmitter release by about 50%. Ex vivo autoradiography, however, demonstrated that iv administration of (-)-(1R,3S)-11 produced a dose-dependent, persistent occupation of 5-HT transporter binding sites but not DA transporter sites.lld:pubmed
pubmed-article:15115403pubmed:languageenglld:pubmed
pubmed-article:15115403pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15115403pubmed:citationSubsetIMlld:pubmed
pubmed-article:15115403pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15115403pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15115403pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15115403pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15115403pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15115403pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15115403pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15115403pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15115403pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15115403pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15115403pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15115403pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15115403pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15115403pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15115403pubmed:statusMEDLINElld:pubmed
pubmed-article:15115403pubmed:monthMaylld:pubmed
pubmed-article:15115403pubmed:issn0022-2623lld:pubmed
pubmed-article:15115403pubmed:authorpubmed-author:FRYDDlld:pubmed
pubmed-article:15115403pubmed:authorpubmed-author:TianXinrongXlld:pubmed
pubmed-article:15115403pubmed:authorpubmed-author:JacobsonArthu...lld:pubmed
pubmed-article:15115403pubmed:authorpubmed-author:RiceKenner...lld:pubmed
pubmed-article:15115403pubmed:authorpubmed-author:DerschChristi...lld:pubmed
pubmed-article:15115403pubmed:authorpubmed-author:RothmanRichar...lld:pubmed
pubmed-article:15115403pubmed:authorpubmed-author:BaumannMichae...lld:pubmed
pubmed-article:15115403pubmed:authorpubmed-author:Flippen-Ander...lld:pubmed
pubmed-article:15115403pubmed:authorpubmed-author:FolkJohn EJElld:pubmed
pubmed-article:15115403pubmed:authorpubmed-author:KimIn JongIJlld:pubmed
pubmed-article:15115403pubmed:authorpubmed-author:ParrishDamonDlld:pubmed
pubmed-article:15115403pubmed:issnTypePrintlld:pubmed
pubmed-article:15115403pubmed:day6lld:pubmed
pubmed-article:15115403pubmed:volume47lld:pubmed
pubmed-article:15115403pubmed:ownerNLMlld:pubmed
pubmed-article:15115403pubmed:authorsCompleteYlld:pubmed
pubmed-article:15115403pubmed:pagination2624-34lld:pubmed
pubmed-article:15115403pubmed:dateRevised2006-11-15lld:pubmed
pubmed-article:15115403pubmed:meshHeadingpubmed-meshheading:15115403...lld:pubmed
pubmed-article:15115403pubmed:meshHeadingpubmed-meshheading:15115403...lld:pubmed
pubmed-article:15115403pubmed:meshHeadingpubmed-meshheading:15115403...lld:pubmed
pubmed-article:15115403pubmed:meshHeadingpubmed-meshheading:15115403...lld:pubmed
pubmed-article:15115403pubmed:meshHeadingpubmed-meshheading:15115403...lld:pubmed
pubmed-article:15115403pubmed:meshHeadingpubmed-meshheading:15115403...lld:pubmed
pubmed-article:15115403pubmed:meshHeadingpubmed-meshheading:15115403...lld:pubmed
pubmed-article:15115403pubmed:meshHeadingpubmed-meshheading:15115403...lld:pubmed
pubmed-article:15115403pubmed:meshHeadingpubmed-meshheading:15115403...lld:pubmed
pubmed-article:15115403pubmed:meshHeadingpubmed-meshheading:15115403...lld:pubmed
pubmed-article:15115403pubmed:meshHeadingpubmed-meshheading:15115403...lld:pubmed
pubmed-article:15115403pubmed:meshHeadingpubmed-meshheading:15115403...lld:pubmed
pubmed-article:15115403pubmed:meshHeadingpubmed-meshheading:15115403...lld:pubmed
pubmed-article:15115403pubmed:meshHeadingpubmed-meshheading:15115403...lld:pubmed
pubmed-article:15115403pubmed:meshHeadingpubmed-meshheading:15115403...lld:pubmed
pubmed-article:15115403pubmed:meshHeadingpubmed-meshheading:15115403...lld:pubmed
pubmed-article:15115403pubmed:meshHeadingpubmed-meshheading:15115403...lld:pubmed
pubmed-article:15115403pubmed:meshHeadingpubmed-meshheading:15115403...lld:pubmed
pubmed-article:15115403pubmed:meshHeadingpubmed-meshheading:15115403...lld:pubmed
pubmed-article:15115403pubmed:meshHeadingpubmed-meshheading:15115403...lld:pubmed
pubmed-article:15115403pubmed:meshHeadingpubmed-meshheading:15115403...lld:pubmed
pubmed-article:15115403pubmed:meshHeadingpubmed-meshheading:15115403...lld:pubmed
pubmed-article:15115403pubmed:year2004lld:pubmed
pubmed-article:15115403pubmed:articleTitleSynthesis and pharmacological evaluation of 3-(3,4-dichlorophenyl)-1-indanamine derivatives as nonselective ligands for biogenic amine transporters.lld:pubmed
pubmed-article:15115403pubmed:affiliationLaboratory of Medicinal Chemistry, Building 8, Room B1-23, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Department of Health and Human Services, Bethesda, Maryland, 20892-0815, USA.lld:pubmed
pubmed-article:15115403pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:15115403pubmed:publicationTypeIn Vitrolld:pubmed
pubmed-article:15115403pubmed:publicationTypeResearch Support, U.S. Gov't, P.H.S.lld:pubmed
pubmed-article:15115403pubmed:publicationTypeResearch Support, U.S. Gov't, Non-P.H.S.lld:pubmed
http://linkedlifedata.com/r...http://linkedlifedata.com/r...pubmed-article:15115403lld:chembl
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:15115403lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:15115403lld:pubmed